Immatics N.V. (IMTX)Healthcare | Biotechnology | Tübingen, Germany | NasdaqCM
9.23 USD
-0.45
(-4.649%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:04 a.m. EDT
The investment case for Immatics is currently fractured by a severe disconnect between its operational narrative and its financial reality. While the company boasts a 'strong buy' analyst consensus driven by promising Phase 3 trial enrollment and a potential pivot beyond its PRAME asset, the hard numbers tell a different story. Revenue has contracted by nearly 60% year-over-year, and the business is burning significant cash with negative operating margins. This fundamental deterioration is reflected in the stock's brutal six-year performance, which has erased over 40% of its value despite some interim recoveries. The short-term outlook remains precarious. The options market is screaming caution, with traders loading up heavily on downside protection while offering almost no leverage for a bounce. This pessimism is rational given the company's inability to generate free cash flow and its reliance on external financing. Although the balance sheet appears robust on paper due to low debt, the rapid burn rate and shrinking revenue base suggest that liquidity could become a constraint if clinical results do not translate into sales quickly. Until the company demonstrates a path to profitability or a clear, funded commercialization strategy, the risk of further value destruction outweighs the speculative upside. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.113683 |
| AutoTheta | 0.116765 |
| AutoETS | 0.116795 |
| AutoARIMA | 0.133114 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 18.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.224 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.309 |
| Revenue per Share | 0.297 |
| Market Cap | 1,261,493,248 |
| Forward P/E | -4.85 |
| Beta | 1.32 |
| Website | https://www.immatics.com |
As of July 11, 2026, 6:04 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in July 2026 puts at strikes below the current price (over 1,300 contracts at the $8 strike versus negligible call volume). Conversely, call activity is sparse and concentrated near-the-money, indicating a lack of bullish conviction for a rally. The disparity suggests the market views the near term as a high-risk environment where capital preservation takes precedence over speculation on a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5486578 |
| Address1 | Paul-Ehrlich-Strasse 15-19 |
| All Time High | 18.42 |
| All Time Low | 0.005 |
| Ask | 9.25 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 420,650 |
| Average Daily Volume3 Month | 475,598 |
| Average Volume | 475,598 |
| Average Volume10Days | 420,650 |
| Beta | 1.321 |
| Bid | 9.21 |
| Bid Size | 1 |
| Book Value | 3.806569 |
| City | Tübingen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Germany |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.23 |
| Current Ratio | 8.775 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.67 |
| Day Low | 9.2 |
| Debt To Equity | 3.309 |
| Display Name | Immatics |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -203,930,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.036 |
| Enterprise To Revenue | 22.067 |
| Enterprise Value | 823,004,288 |
| Eps Current Year | -1.94362 |
| Eps Forward | -1.90238 |
| Eps Trailing Twelve Months | -1.95 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 49 7071 5397 900 |
| Fifty Day Average | 10.3324 |
| Fifty Day Average Change | -1.1024008 |
| Fifty Day Average Change Percent | -0.10669358 |
| Fifty Two Week Change Percent | 54.865776 |
| Fifty Two Week High | 12.41 |
| Fifty Two Week High Change | -3.1800003 |
| Fifty Two Week High Change Percent | -0.256245 |
| Fifty Two Week Low | 5.05 |
| Fifty Two Week Low Change | 4.1799994 |
| Fifty Two Week Low Change Percent | 0.8277226 |
| Fifty Two Week Range | 5.05 - 12.41 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,544,625,000,000 |
| Float Shares | 69,585,773 |
| Forward Eps | -1.90238 |
| Forward P E | -4.851817 |
| Free Cashflow | -110,854,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 678 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -163,814,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17581 |
| Held Percent Institutions | 0.79523003 |
| Implied Shares Outstanding | 136,673,161 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. |
| Long Name | Immatics N.V. |
| Market | us_market |
| Market Cap | 1,261,493,248 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_8986547 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -214,406,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,262,860,007 |
| Number Of Analyst Opinions | 7 |
| Open | 9.53 |
| Operating Cashflow | -184,463,008 |
| Operating Margins | -8.67893 |
| Payout Ratio | 0.0 |
| Phone | 49 7071 5397 0 |
| Pre Market Change | 0.17000008 |
| Pre Market Change Percent | 1.8418211 |
| Pre Market Price | 9.4 |
| Pre Market Time | 1,784,032,555 |
| Previous Close | 9.68 |
| Price Eps Current Year | -4.7488704 |
| Price Hint | 2 |
| Price To Book | 2.4247556 |
| Price To Sales Trailing12 Months | 33.823822 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.296 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.450001 |
| Regular Market Change Percent | -4.64877 |
| Regular Market Day High | 9.67 |
| Regular Market Day Low | 9.2 |
| Regular Market Day Range | 9.2 - 9.67 |
| Regular Market Open | 9.53 |
| Regular Market Previous Close | 9.68 |
| Regular Market Price | 9.23 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 178,107 |
| Return On Assets | -0.22438 |
| Return On Equity | -0.43208998 |
| Revenue Growth | -0.59 |
| Revenue Per Share | 0.297 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 136,673,161 |
| Shares Percent Shares Out | 0.0396 |
| Shares Short | 5,408,927 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,796,236 |
| Short Name | Immatics N.V. |
| Short Percent Of Float | 0.0573 |
| Short Ratio | 10.25 |
| Source Interval | 15 |
| Symbol | IMTX |
| Target High Price | 25.0 |
| Target Low Price | 12.2 |
| Target Mean Price | 18.88571 |
| Target Median Price | 18.0 |
| Total Cash | 453,569,984 |
| Total Cash Per Share | 3.319 |
| Total Debt | 15,081,000 |
| Total Revenue | 37,296,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.0821 |
| Two Hundred Day Average Change | -0.8521004 |
| Two Hundred Day Average Change Percent | -0.08451616 |
| Type Disp | Equity |
| Volume | 178,107 |
| Website | https://www.immatics.com |
| Zip | 72,076 |